Fenghua Wu | Oncology Pharmaceuticals | Best Researcher Award

Fenghua Wu | Oncology Pharmaceuticals | Best Researcher Award

Mrs. Fenghua Wu at Hubei university of chinese medcine, China.

Mrs. Fenghua Wu is a distinguished researcher and educator with a doctoral degree from Tongji Medical College, Huazhong University of Science and Technology 🎓. She specializes in physiology and oncology, focusing on the tumor microenvironment and tumor immunology 🔬. Her groundbreaking research explores the regulatory mechanisms of natural and traditional Chinese medicines in cancer treatment 🌿. As a principal investigator for the National Natural Science Foundation of China, she has published extensively in SCI-indexed journals 📚. Honored as a “Teaching Expert” and COVID-19 frontline contributor 🏅, she also serves as a Guest Editor for Frontiers in Immunology.

Publication Profile 

Scopus

Education

Mrs. Fenghua Wu earned her doctoral degree from Tongji Medical College, Huazhong University of Science and Technology 🏥. She currently teaches physiology and is actively engaged in oncology research 🔬 at her institution. Her work focuses on exploring cancer biology and its treatment mechanisms. As a leading scientist, she has served as the principal investigator for prestigious projects funded by the National Natural Science Foundation of China 🇨🇳. Her academic dedication and scientific contributions reflect her commitment to advancing knowledge in the field of cancer research and education.

Professional Memberships

Mrs. Fenghua Wu is a proud member of the Chinese Anti-Cancer Association (CACA) 🧬, a prestigious national organization committed to advancing cancer research, treatment, and public health awareness in China 🇨🇳. Her affiliation with CACA underscores her dedication to the oncology field and her active participation in collaborative efforts aimed at combating cancer through scientific innovation and knowledge exchange 🔬. As part of this professional body, she stays connected with leading experts, contributes to cancer-related initiatives, and continuously enhances her expertise to benefit patients and students alike.

Research Focus 

Mrs. Fenghua Wu’s research focus lies at the intersection of tumor immunology, traditional Chinese medicine, and molecular oncology 🧬. She explores how natural compounds—such as dihydroartemisinin and capsaicin—can modulate immune responses and inhibit cancer progression, particularly in breast cancer and tongue squamous cell carcinoma (TSCC) 🎯. Her studies often center on critical pathways like TNF-α, PI3K/AKT/mTOR, and TGF-β1, highlighting her commitment to advancing immunotherapy and targeted therapies 🧪. Her category of research can be broadly classified under Cancer Pharmacology, Immuno-Oncology, and Natural Product-Based Therapeutics.

Publication Top Notes

  • Dihydroartemisinin restrains angiogenesis through the TNF-α pathway to enhance the efficacy of anti-PD-1 immunotherapy in breast cancer
  • Capsaicin combined with cisplatin inhibits TGF-β1-induced EMT and TSCC cells migration via the Claudin-1/PI3K/AKT/mTOR signaling pathway

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Prof. Dr. Takuma Hayashi, National Hospital Organization Kyoto Medical Center, Japan

Prof. Dr. Takuma Hayashi is a renowned Japanese physician-scientist specializing in gynecologic oncology. 🎓 He earned his PhD from the University of Tokyo and trained at MIT’s Whitehead Institute 🧠, contributing to Nobel-linked research. Currently a professor at Shinshu University and Section Head at Kyoto Medical Center 🏥, his groundbreaking work on uterine leiomyosarcoma (LMS) identified LMP2 deficiency as a key biomarker 🔎. Through precision medicine and genomic profiling 🧬, his research has significantly advanced diagnostics and treatment strategies for LMS. With over 30 years of funded research, Dr. Hayashi is globally recognized for revolutionizing women’s cancer care.

Publication Profile

Scopus

Education

Prof. Dr. Takuma Hayashi is a distinguished physician-scientist known for bridging fundamental cancer research with clinical applications. 👨‍⚕️🔬 He is a Professor at Shinshu University Graduate School of Medicine and Section Head at Japan’s National Hospital Organization Kyoto Medical Center. 🎓🏥 Dr. Hayashi earned his PhD from the University of Tokyo and completed postdoctoral training at MIT’s Whitehead Institute under Dr. Rick A. Young. 🎓🇯🇵🇺🇸 He contributed to Nobel Prize-linked AIDS vaccine research with Dr. David Baltimore. With over 30 years of NIH and JSPS funding, his work focuses on molecular research in uterine leiomyosarcoma and ovarian cancer, collaborating with Nobel Laureate Dr. Susumu Tonegawa.

Experience

Prof. Dr. Takuma Hayashi has pioneered precision medicine breakthroughs in uterine leiomyosarcoma (LMS) treatment. 🧬💉 His team used cancer genome panel testing to tailor therapies based on each tumor’s unique genetics. For example, immunotherapy with pembrolizumab led to significant tumor regression, while targeted treatment with pazopanib stabilized disease for months. 🎯💊 Dr. Hayashi’s background from the University of Tokyo and MIT supports his innovative approach. 🚀 His ongoing goals include developing diagnostics, launching clinical trials, expanding global collaboration, and improving patient access to genomic profiling. 🌍💡 His work offers new hope for women facing this aggressive cancer.

Research Focus

Prof. Dr. Takuma Hayashi’s research primarily focuses on molecular oncology and infectious diseases, particularly cancer biomarkers and viral infections. 🧬🔬 His work on uterine leiomyosarcoma involves discovering key diagnostic biomarkers like LMP2 to improve early detection and treatment strategies in aggressive cancers. 🩺🎗️ Additionally, Dr. Hayashi explores infectious diseases such as avian influenza and COVID-19, emphasizing the One Health approach to prevent viral spread between animals and humans. 🦠🌍 His interdisciplinary research bridges cancer biology, immunology, and public health, aiming to develop precision medicine therapies and enhance global disease control efforts.

Publication Top Notes

THE ROLE OF LIVE BIRD MARKETS SHOULD BE EMPHASIZED IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA INFECTIONS

THE IMPORTANCE OF ONE HEALTH IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA/H5N1

Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with Gastric Cancer Associated with Hereditary Breast and Ovarian Cancer

DEVELOPMENT OF ENDOSALPINGIOSIS IN PATIENTS WITH A HISTORY OF BREAST CANCER

High Transferability of Neutralizing Antibodies against SARS-CoV-2 to Umbilical Cord Blood in Pregnant Women Vaccinated with BNT162b2 XBB.1.5: A Retrospective Cohort Study

POTENTIAL DIAGNOSTIC BIOMARKERS FOR HUMAN MESENCHYMAL TUMORS, ESPECIALLY LMP2/Β1I AND CYCLIN E1/MIB1 DIFFERENTIAL EXPRESSION: PRUM-IBIO STUDY